[CAS NO. 1423715-37-0] Seclidemstat (SP-2577)
Please click "REQUEST A QUOTE" button if you need other sizes or
custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis,
please:
PRODUCTS SPECIFICATIONS [1423715-37-0]
Catalog
SLK-S6722
Brand
Selleck
CAS
1423715-37-0
DESCRIPTION [1423715-37-0]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 450.94 |
| Molecular Formula | C20H23ClN4O4S |
| SMILES | O=C(N/N=C(C1=CC(Cl)=CC=C1O)\C)C2=CC=CC(S(=O)(N3CCN(C)CC3)=O)=C2 |
For research use only.
Storage
3 years,-20°C,powder
1 years,-80°C,in solvent
1 years,-80°C,in solvent
Shipping
Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)
Preparing Stock Solutions
| 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2176 mL | 11.0879 mL | 22.1759 mL |
| 5 mM | 0.4435 mL | 2.2176 mL | 4.4352 mL |
| 10 mM | 0.2218 mL | 1.1088 mL | 2.2176 mL |
| 50 mM | 0.0444 mL | 0.2218 mL | 0.4435 mL |
Description
Seclidemstat (SP-2577) is a potent and orally bioavailable inhibitor of with IC50 of 13 nM. Seclidemstat (SP-2577) has potential antineoplastic activity.
Targets
| LSD1/KDM1A [1] (Cell-free assay) |
| 13 nM |
In vitro
The combination therapy of Seclidemstat (SP-2577) with checkpoint inhibitors may induce or augment immunogenic responses of SWI/SNF-mutated ovarian cancers. Seclidemstat promotes endogenous retroviruses (ERVs) expression and activation of IFNβ pathway in small cell carcinoma of the ovary hypercalcemic type (SCCOHT) cell lines. Seclidemstat (3 μM) promotes PD-L1 expression in SCCOHT COV 434 pIND 20 BRG1-2.7 cell line.
References
Powered by Arctom Copyright © 2025 Arctom.
All rights reserved.